The UK government’s 10 Year Health Plan sets a bold ambition for the NHS, shifting from analogue to digital, from hospital to community, and from cure to prevention. For the life sciences sector, this aligns closely with long standing priorities around earlier detection, precision health, and the integration of real‑world data into care pathways. At-home diagnostics and AI detection can support this push for prevention, flagging health changes before they would be picked up by clinical teams. There’s a huge opportunity for at-home diagnostics and AI detection to support prevention – but first, they need to scale.
At-home diagnostics such as blood glucose and genetic tests are enabling more people to track, catch, and manage health conditions from the comfort of their own homes. At the same time, AI is reshaping the wider life sciences landscape. AI‑driven clinical decision support is personalising treatment, improving operational efficiency, and identifying subtle changes in an individual’s health status before they become clinically visible. For industry, this represents a major step toward integrating AI‑derived insights with established diagnostic modalities and real‑world evidence.
Importantly, AI can enable self-management and home testing at scale through hyper-personalised coaching based on an individual’s goals, prompting behavioural changes based on real-life data and escalating to clinicians when necessary. For life sciences, this signals a shift toward a new era of digitally powered prevention. It’s an opportunity to combine diagnostics, AI, and population‑level data to deliver earlier intervention, improve lifetime outcomes, and reduce demand on overstretched healthcare systems.
PA Consulting’s latest research, conducted with senior healthcare leaders from Directors to Chief Officers, found that 70 percent of leaders see at-home diagnostics and screening as the most promising digital prevention initiative of the next decade. Support for these tools is strong, with 80 percent strongly believing that digital tools could reduce health inequalities.
But while there are plenty of pilots out there, they don’t yet exist at scale. How can promising pilots evolve from place-level to support whole populations? Which fundamental blocks are missing, and who is responsible for putting them in place?
At-home diagnostics and AI-enabled detection: where are we now?
At-home diagnostics is an important part of today’s healthcare system. FIT tests are supporting Bowel Cancer screening. A world‑first remote monitoring trial for people with motor neurone disease (MND) is enabling breathing support adjustments from home. The NHS is also trialling giving patients the ability to update their health record with important health markers, starting with blood pressure data – an important first step in giving people more control over their data, and linking data with third-party devices like wearables. Last year, the NHS began trialling a new digital health check for CVD via the NHS App, avoiding the need for people to attend local surgeries by offering an at-home blood test for cholesterol. Looking ahead, NHS England will introduce at‑home HPV testing. All of this reduces hospital pressure and makes healthcare far more accessible.
On the AI side, the NHS is implementing the first AI‑driven early warning system, scanning real‑time healthcare data to flag safety risks and prevent issues before they escalate. In maternity services, the Maternity Outcomes Signal System uses near‑real‑time data to identify stillbirth, neonatal death, and brain injury, enabling faster interventions. NHS England has deployed AI across 66 NHS Trusts to support chest imaging and lung diagnostics. Diabetic retinopathy uses AI image analysis, NHS AI can spot cancer cases missed by doctors, and rich data from wearables such as Atrial fibrillation detection algorithms can aid prevention. In future, AI will monitor hospital databases for patterns linked to injury, deaths, or malpractice, triggering earlier inspections and intervention.
These tools mirror advances already transforming the life sciences sector – AI‑enabled phenotype detection, multimodal data integration, and early‑signal surveillance that would traditionally rely on laboratory‑based diagnostics. Right now, these are promising pilots. The next step is to make sure they can scale, and that this scale can be sustained.
System-level changes to drive scalability ‑level changes
Moving at-home diagnostics and AI-enabled detection from promising pilots to population‑level change requires coordinated action across the system. It starts with data – high quality and quantity data is vital to scale AI tools and systems. From here, pathway redesign will open up avenues for new tools and diagnostics to materially impact preventative prescribing decisions. Incentivising the system to adopt diagnostics and AI-enabled tools will sustain momentum and support local teams to apply transformative tools in a meaningful way.
-
Build data and interoperability foundations
Diagnostics and AI‑enabled detection can only scale when data flows securely and consistently across settings. Investing in shared data standards, interoperable platforms, and real‑time analytics – mirroring the direction set out in the 10 Year Health Plan – will allow clinicians to act on, and automate insights at scale.
Trust is particularly important for at-home diagnostics; their efficacy and effectiveness rely on non-professionals being able to understand and interpret their own health data. Trust is also crucial for clinicians, who need to trust that at-home diagnostics will provide reports based on accurate remote monitoring – reducing false positives while ensuring true positives are not missed. In life sciences terms, this is about ensuring diagnostic sensitivity, specificity and reproducibility match clinical standards even outside controlled environments – a challenge that extends well beyond diagnostics, as explored in recent analysis of real-world outcomes in anti-obesity medication.
-
Redesign pathways around early detection and intervention
At‑home diagnostics and predictive AI have the potential to transform existing pathways – the challenge is how to use AI and new digital tools to radically redesign pathways rather than automate existing ones. This means redesigning referral routes, clarifying escalation points, and embedding digital-first prevention into Integrated Care System strategies, reflecting the NHS’s long‑term plan to rebalance care towards community and prevention. This needs to start in the areas of greatest need where demand is highest, providing an evidence base to monitor successes and expand use cases.
At-home diagnostics tests need to be simple and robust enough for non-professionals to use correctly in home environments. Tests must be easily and promptly available, but with the right clinical checks and balances – presenting an opportunity for NHS bodies to partner with tech providers to co-develop solutions.
-
Align incentives to support prevention at local level
Incentives come from the top – when senior leaders set the direction, local teams are empowered to follow. Importantly, incentives need to build in local flexibility so that chosen solutions, whether a specific at-home diagnostic or a shared AI system for NHS Trusts, can meet local population health requirements.
To sustain broader adoption of at-home diagnostics and AI-driven tools, the health system needs to make advanced solutions a core part of commissioning decisions. Just as payers evaluate new diagnostics and digital biomarkers in life sciences, value‑based adoption must be baked into commissioning. With these foundations in place, the NHS and its life sciences partners can scale proven innovations and deliver on the ambition of a more resilient, digitally-powered, preventative health system.
Author Bio
James Davis
James Davis is a healthcare expert at PA Consulting, the global innovation and transformation consultancy. He specialises in delivering digital and organisational transformation programmes and helped to set up and deliver the technology platform that supported the national rollout of COVID and flu vaccinations. More recently, James has worked with the Digital Prevention team in NHS England to shape thinking around the Government’s 10‑Year Health Plan, helping to visualise a future in which patients are supported by a new digital ecosystem to better manage and maintain their health.
Disclaimer: This article reflects the author’s own analysis and is provided for informational purposes only; it does not constitute medical, legal, or official editorial advice from Life Science Daily News. The author is a Healthcare Expert at PA Consulting, a global innovation and transformation consultancy with commercial interests in NHS digital transformation.
